Information Provided By:
Fly News Breaks for May 20, 2019
NBIX
May 20, 2019 | 16:31 EDT
Credit Suisse analyst Evan Seigerman initiated Neurocrine with an Outperform rating and a $95 price target, calling the stock a Top Pick - SMID Cap. Seigerman believes Neurocrine's Ingrezza is "the best-in-class treatment" for tardive dyskinesia, or TD, and he expects it will drive revenue and earnings growth over the next few years. He also believes the company's pipeline has underappreciated upside potential, with assets for Parkinson's disease and congenital adrenal hyperplasia.
News For NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.